Direct Cross-Titration Without Tapering Rexulti
You can directly switch from Rexulti 2 mg to Latuda without tapering the Rexulti, using a cross-titration approach over 1-2 weeks. Both medications are atypical antipsychotics with similar mechanisms and no evidence suggests withdrawal symptoms from abrupt discontinuation at this dose.
Switching Strategy
Week 1 Approach (Recommended)
- Day 1-3: Start Latuda 40 mg with food (≥350 calories) while continuing Rexulti 2 mg
- Day 4-7: Continue Latuda 40 mg, reduce Rexulti to 1 mg
- Day 8 onward: Continue Latuda 40 mg, discontinue Rexulti completely
Alternative Week 2 Approach (If More Cautious)
- Week 1: Start Latuda 40 mg while maintaining Rexulti 2 mg
- Week 2: Continue Latuda 40 mg, discontinue Rexulti
After the switch is complete, Latuda can be titrated to 80-120 mg daily based on response and tolerability 1.
Rationale for This Approach
No formal taper is required for Rexulti at 2 mg. The FDA label for Rexulti 2 contains no warnings about withdrawal symptoms or requirements for gradual discontinuation. Unlike benzodiazepines, which require slow tapers to prevent seizures and withdrawal 3, 4, antipsychotics at therapeutic doses can typically be switched more directly.
Research on switching antipsychotics demonstrates that cross-titration over 1-2 weeks is safe and effective 1. In a study of 240 patients switching to lurasidone from other antipsychotics, the previous medication was tapered to 50% by day 7 and discontinued by week 2, with only 7.9% experiencing treatment failure 1.
Addressing the Insomnia Issue
Latuda may actually improve the insomnia that prompted this switch. While Rexulti can cause insomnia as a side effect, lurasidone has demonstrated sleep-promoting properties:
- Increased total sleep time by 28.4 minutes versus placebo 5
- Improved sleep efficiency and reduced wake time after sleep onset 5
- Enhanced sleep maintenance without affecting sleep onset 5
- Improved subjective sleep measures in patients with depression 6
This is attributed to lurasidone's 5-HT7 receptor antagonism, which modulates sleep architecture 7. The medication should be taken with food (at least 350 calories) at bedtime to optimize absorption and leverage its sleep-promoting effects.
Monitoring During the Switch
Watch for these specific issues during the transition:
Potential Problems:
- Akathisia: Occurs in 12.5% with lurasidone but rarely leads to discontinuation 1. Manage with dose reduction or propranolol if needed
- Transient sedation: May occur in first 1-2 weeks as lurasidone reaches steady state
- Nausea: Take with adequate food (≥350 calories) to minimize this
Positive Changes to Expect:
- Improved sleep continuity within 1-2 weeks 5
- Potential weight reduction if patient gained weight on Rexulti 1
- Improved metabolic parameters (lipids, glucose) 1
Critical Dosing Consideration
Latuda MUST be taken with at least 350 calories of food. Without food, absorption decreases by 50%, rendering the medication potentially ineffective. This is the most common cause of treatment failure with lurasidone 8.
If Patient Has Been on Rexulti Long-Term
Even for patients on Rexulti for extended periods (>1 year), no evidence supports the need for ultra-slow tapers as would be required for benzodiazepines 3, 4. The 1-2 week cross-titration remains appropriate. The guideline recommendation for 10% monthly tapers 4 applies to opioids and benzodiazepines due to their specific withdrawal syndromes, not to antipsychotics at therapeutic doses.